Quest Diagnostics (DGX)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$212.26-0.56%
Close 2026-07-07 · 1-day change
Reading DGX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DGX free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DGX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DGX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
DGX represents a durable compounder in the healthcare sector. The current thesis state is intact, supported by recent strong financial performance, although management has struggled to meet its growth priorities.
The market appears to price DGX as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully believe in the company's ability to achieve its stated growth objectives.
Fundamentals may continue to show moderate risk, with management focused on increasing revenue and earnings per share (EPS) growth. However, recent declines in revenue and EPS indicate that achieving these goals may take time.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable backdrop for DGX, but any negative shifts could pose risks.
Overall, DGX's prospects depend on both its internal execution and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat and the recent approval of a new cancer test in New York, which can increase revenue growth. There are no significant threats noted that would counter this positive shift.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the EPS target is met, it shows management cares about making more money. It also shows they manage costs well.
Confirms:Adjusted EPS meets or exceeds $10.70 for the full year.
Disproves:Adjusted EPS falls below $10.50 for the full year.
Why it matters: A higher adjusted EPS shows better earnings. This matches management's goal to grow EPS.
Confirms:Adjusted EPS for Q2 reaches or exceeds $2.75.
Disproves:Adjusted EPS for Q2 falls below $2.50.
Why it matters: Earnings results will show if revenue growth is improving or still behind. Investors will react to the growth trend.
Confirms:Q2 earnings report shows revenue growth above 5% year over year.
Disproves:Q2 earnings report shows revenue growth below 0% year over year.
Why it matters: Good management of capital spending helps EPS growth. This affects the company's financial health.
Confirms:Management plans to cut capital spending by 10% or more.
Disproves:Management says capital spending is going up beyond current levels.
Why it matters: Strong revenue growth would show that Quest Diagnostics is improving its sales strategy. It would also support management's goal of increasing revenue growth.
Confirms:Q2 revenue growth exceeds 7% year over year.
Disproves:Q2 revenue growth is below 6% year over year.
Why it matters: If it drops below this level, it may show cash flow problems that affect spending.
Confirms:Cash flow from operations was below $1.75 billion.
Disproves:Cash flow from operations remains at or above $1.75 billion.
Why it matters: A drop in revenue growth could signal a shift in the sector's growth phase. This would impact investor confidence.
Confirms:Revenue growth falls below the sector median of 1% year over year.
Disproves:Revenue growth remains above the sector median of 1% year over year.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Timothy Wentworth's experience may affect decisions. His role on the board may help growth.
Confirms:The company shares new plans or partnerships after he is elected.
Disproves:No major changes in plans or results after he is elected.
Why it matters: The debt issuance may change Quest's ability to manage money and invest. Watching how they use it will show how they balance growth and debt.
Confirms one read:Management says they are using the debt money well for growth projects.
Confirms the other:Management says the money is mainly for paying off debt, not for growth projects.
Why it matters: Doing this well may help Quest's market position and increase future revenue.
Confirms:A big milestone was reached in the Co-Lab Solutions project.
Disproves:There is a delay or setback in the Co-Lab Solutions project timeline.